Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peginterferon · 1 trial · 1 indication
PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse. PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.
| Arm | Type | Description |
|---|---|---|
| Peginterferon α-2b | EXPERIMENTAL | Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years. |
| No Treatment | NO_INTERVENTION | Participants will be observed and will receive no treatment. |
| Name | Type | Description |
|---|---|---|
| Peginterferon | DRUG | Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years. |
Inclusion Criteria: * Must demonstrate willingness to participate in the study and to adhere to dose and visit schedules * Must be ≤85 years of age of either sex, and any race * Must have stage II or III multiple myeloma with a histological confirmation consistent with the diagnosis of multiple my...
Top 20 of 25 competitors
Peginterferon is being studied as a maintenance therapy for people with multiple myeloma who have responded to induction therapy. It is an oncology asset developed by Merck & Company, Inc. under the ticker MRK. The program is in Phase 3 development, and the single registered trial in this indication has completed.
Peginterferon targets IFNAR1 and IFNAR2, the two subunits of the type I interferon receptor. It acts as an agonist at this receptor complex. By binding and activating IFNAR1 and IFNAR2, peginterferon triggers interferon signaling, which is the basis for its evaluation as a maintenance treatment in multiple myeloma.
Peginterferon is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the Phase 3 multiple myeloma maintenance program for this agent. The asset is identified in ChEMBL under the identifier CHEMBL1201560.
Peginterferon is in Phase 3 development for multiple myeloma. It is an investigational agent and is not approved for this use. The Phase 3 trial in this program has completed, and no trials are currently listed as active for this indication.
Peginterferon has been evaluated in the Phase 3 trial NCT00732641, titled Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy. That trial enrolled 244 participants, was randomized, used a no-treatment control, and has completed. Participants were 18 years or older.